Bristol Myers Squibb dropped another CTLA-4 program from its decade-long research collaboration with CytomX after the big pharma reviewed its portfolio.
CytomX announced the change in
its 2023 financial results
on Monday, noting that the companies are still collaborating on multiple preclinical programs, including T cell engagers. It was notified by BMS on March 6 that the anti-CTLA-4, BMS-986288, won’t advance beyond its current trial. That
Phase II study
is investigating the drug as a monotherapy and in combination with nivolumab for patients with advanced solid tumors and is set to wrap up in April, according to clinicaltrials.gov.